Miami, FL, November 19, 2002
Noven Presents Pre-Clinical Study Data At AAPS Annual Meeting
-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) announced that it presented the results of several pre-clinical transdermal research projects at the recent 2002 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. The full text of these presentations is available on Noven’s website at www.noven.com under "Research/Scientific Publications."
"We are very pleased with the results of our ongoing pre-clinical development programs," said Juan Mantelle, Noven’s Chief Technical Officer. "The AAPS presentations represent just a small portion of our comprehensive development efforts, and reflect Noven’s commitment to advancing transdermal science and to maintaining a robust new product pipeline."
At the AAPS meeting, David Kanios, Noven’s Associate Director – Research & Development, presented "In-Vitro Permeation of Low Molecular Weight Amine Drugs in Transdermal Drug Delivery Systems." The presentation summarized the results of three pre-clinical studies designed to establish formulation parameters for the transdermal delivery of methamphetamine and d-amphetamine, which could be used in the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Study results indicated that varying the ratios of acrylic and silicone pressure sensitive adhesives allows flexibility to attain a desired profile for the delivery of both methamphetamine and d-amphetamine via an adhesive matrix transdermal system.
David Houze, Noven Senior Research Scientist, presented the results of a study entitled "In-Vitro Transdermal Permeation Performance of Drug and Pro-drug Combinations." Using norethindrone and norethindrone acetate, this study demonstrated that higher skin permeation rates than those obtained from a single-drug formulation can be achieved with the addition of a pro-drug to the adhesive matrix.
Chensheng Li, Noven Senior Research Chemist, presented the results of a study entitled "Kinetic Study of Threo-Methylphenidate Degradation Reaction to Erythro Isomer in MethyPatch Transdermal System," which supported the use of an accelerated three-month model to accurately test the stability of a transdermal methylphenidate system, and possibly other transdermal systems.
Viet T. Nguyen, Noven Process Development Engineer, presented the results of a study entitled "In-Vitro to In-Vivo Evaluation for Scopolamine Transdermal Delivery." This study demonstrated the correlation between Noven’s in vitro delivery model and actual in vivo plasma concentrations for transdermal scopolamine, and helped refine Noven’s overall in vitro/in vivo modeling capabilities.
"Noven's transdermal technology has expanded the universe of molecules that can be delivered transdermally, making patch formulations possible in a broad range of therapeutic categories," said Pavan Handa, Noven's Executive Director – Business Development. "This has created an abundance of development opportunities for Noven and for third party licensees. Our continuing business development goal is to strike mutually beneficial development and license arrangements, and we welcome inquiries and proposals in this regard."
The majority of Noven's development projects utilize Noven's patented DOT Matrix™ transdermal patch technology, which is the delivery platform underlying the Vivelle-Dot® and CombiPatch® hormone therapy patches, and MethyPatch®, Noven's developmental transdermal methylphenidate patch for ADHD (New Drug Application pending). DOT Matrix technology permits Noven to deliver predictable therapeutic doses of a wide range of prescription therapies through discreet, comfortable and adherent patches that are well suited to active lifestyles.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot®, licensed to Novogyne Pharmaceuticals, and Estradot®, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch®, licensed to Novogyne Pharmaceuticals, and Estalis®, licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch® for Attention-Deficit Hyperactivity Disorder, Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal drug delivery systems. For additional information on Noven, visit www.noven.com.
Investors & Media
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
Business Development & Licensing
Executive Director – Business Development